United Therapeutics Corp. (UTHR)
591.11
-2.20
(-0.37%)
USD |
NASDAQ |
Nov 13, 16:00
591.11
0.00 (0.00%)
After-Hours: 19:59
United Therapeutics Net Income (Quarterly) : 258.60M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 258.60M |
| June 30, 2026 | 333.00M |
| March 31, 2026 | 274.90M |
| December 31, 2025 | 364.30M |
| September 30, 2025 | 338.70M |
| June 30, 2025 | 309.50M |
| March 31, 2025 | 322.20M |
| December 31, 2024 | 301.30M |
| September 30, 2024 | 309.10M |
| June 30, 2024 | 278.10M |
| March 31, 2024 | 306.60M |
| December 31, 2023 | 217.10M |
| September 30, 2023 | 267.60M |
| June 30, 2023 | 259.20M |
| March 31, 2023 | 240.90M |
| December 31, 2022 | 132.10M |
| September 30, 2022 | 239.30M |
| June 30, 2022 | 116.00M |
| March 31, 2022 | 239.90M |
| December 31, 2021 | 112.20M |
| September 30, 2021 | 162.70M |
| June 30, 2021 | 172.60M |
| March 31, 2021 | 28.30M |
| December 31, 2020 | 98.80M |
| September 30, 2020 | 171.20M |
| Date | Value |
|---|---|
| June 30, 2020 | 107.10M |
| March 31, 2020 | 137.70M |
| December 31, 2019 | 52.60M |
| September 30, 2019 | 132.40M |
| June 30, 2019 | 205.10M |
| March 31, 2019 | -494.60M |
| December 31, 2018 | 65.30M |
| September 30, 2018 | 106.50M |
| June 30, 2018 | 172.90M |
| March 31, 2018 | 244.50M |
| December 31, 2017 | 19.00M |
| September 30, 2017 | 276.30M |
| June 30, 2017 | -56.00M |
| March 31, 2017 | 178.60M |
| December 31, 2016 | 110.30M |
| September 30, 2016 | 161.80M |
| June 30, 2016 | 206.10M |
| March 31, 2016 | 235.50M |
| December 31, 2015 | 104.64M |
| September 30, 2015 | 464.42M |
| June 30, 2015 | 99.21M |
| March 31, 2015 | -16.64M |
| December 31, 2014 | 115.94M |
| September 30, 2014 | -25.24M |
| June 30, 2014 | 111.85M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Liquidia Corp. | -236.33M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Exelixis, Inc. | 218.10M |
| Gilead Sciences, Inc. | 2.429B |
| Insmed, Inc. | -100.32M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 832.50M |
| Total Expenses (Quarterly) | 573.90M |
| EPS Diluted (Quarterly) | 5.709 |
| Enterprise Value | 23.08B |
| Gross Profit Margin (Quarterly) | 88.10% |
| Profit Margin (Quarterly) | 31.06% |
| Earnings Yield | 4.48% |
| Operating Earnings Yield | 5.06% |
| Normalized Earnings Yield | 4.304 |